Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals (RYTM)
NASDAQ:RYTM
RYTM Stock Chart & Stats
$106.06
-$0.41(-0.68%)
At close: 4:00 PM EST
$106.06
-$0.41(-0.68%)
Day’s Range― - ―
52-Week Range$45.91 - $122.20
Previous CloseN/A
Volume91.33K
Average Volume (3M)798.22K
Market Cap
$7.56B
Enterprise Value$6.60B
Total Cash (Recent Filing)$416.05M
Total Debt (Recent Filing)$151.00M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Mar 04, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding66,736,050
10 Day Avg. Volume576,246
30 Day Avg. Volume798,217
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)20.75
Price to Sales (P/S)26.24
P/FCF Ratio-29.98
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue37.84
Enterprise Value/Gross Profit42.33
Enterprise Value/Ebitda-39.03
Forecast
1Y Price Target
$141.00Price Target Upside32.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-2.7
Revenue Forecast (FY)$292.97M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressPositive Phase 2 data in Prader-Willi syndrome showing BMI and hyperphagia improvements support advancing setmelanotide into a registrational Phase 3 trial, improving prospects for regulatory success and market access.
Commercial ReadinessCommercial preparedness for a hypothalamic obesity indication, with a large identified patient population, indicates potential for a meaningful revenue ramp upon regulatory approval.
Pipeline DiversificationAdvancement of next-generation programs such as weekly RM-718 and bivamelagon provides additional future value drivers beyond the lead therapy and broadens long-term growth optionality.
Bears Say
Competitive AttentionExtensive focus on larger biotech peers within the same coverage report may draw investor capital and attention away from Rhythm, weakening trading interest.
Information UncertaintyLack of material detail in the excerpts creates analyst uncertainty about Rhythm's outlook and could suppress investor confidence until the full research note is disclosed.
Launch Uptake RiskPotential slower uptake for a hypothalamic obesity launch due to limited dedicated treatment centers and modest patient advocacy engagement could constrain early commercial momentum even after approval.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was $45.91 and its highest was $122.20 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is $7.56B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 47 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.708 by -$0.112.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.82.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 66,736,050 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.708. Following the earnings report the stock price went down -7.693%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in RYTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$141.00 (32.94% Upside)
$141.00 (32.94% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 123.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.2%
Last 30 Days ▲ 13.3%
Last 30 Days ▲ 13.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.65%
12-Months-Change
Fundamentals
Return on Equity
-240.36%
Trailing 12-Months
Asset Growth
39.41%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
RYTM Company Deck
RYTM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Rhythm Pharmaceuticals demonstrated strong revenue growth and regulatory progress, particularly for IMCIVREE in hypothalamic obesity. While international revenue faced challenges, the company's successful equity offering and promising data in BBS highlight a positive outlook. R&D costs are rising, but the overall sentiment remains optimistic.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$141.00
▲(32.94% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Avidity Biosciences
―
Abivax SA Sponsored ADR
―
Ownership Overview
Currently, No data available
---